Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylating therapy in high-risk myelodysplastic syndrome (MDS) patients, as azacitidine treatment has been associated with a PI-PLCbeta1-specific promoter demethylation, and induction of PI-PLCbeta1 gene and protein expression. However, little is known about the molecular effect of azacitidine in low-risk MDS or the functional mechanisms linked with azacitidine effect on PI-PLCbeta1 promoter. In the present study, we further investigated the role of epigenetic regulation of PI-PLCbeta1, mainly focusing on the structure of the PI-PLCbeta1 promoter. We first examined the effect of azacitidine on PI-PLCbeta1 promoter methylation and gene expression in low-risk MDS. Moreover, we studied the expression of key molecules associated with the nuclear inositide signaling pathways, such as cyclin D3. By applying a chromatin immunoprecipitation method, we also studied the correlation between the demethylating effect of azacitidine and the degree of recruitment to PI-PLCbeta1 promoter of some transcription factors implicated in hematopoietic stem cell proliferation and differentiation, as well as of the methyl-CpG-binding domain proteins, which specifically interact with methylated DNA. Taken together, our results hint at a specific involvement of PI-PLCbeta1 in epigenetic mechanisms, and are particularly consistent with the hypothesis of a role for PI-PLCbeta1 in azacitidine-induced myeloid differentiation.
INTRODUCTION
Many human cancers are characterized by aberrant signal transduction pathways, resulting in increased proliferation, inhibition of apoptosis and altered cell differentiation.
1,2 Indeed, both phosphoinositide-phospholipase C (PI-PLC) beta1 and the PI3K/ Akt/mTOR pathways can have important roles in normal physiology and in neoplastic transformation. 3 --5 In addition, PI-PLCbeta1 molecular targets, such as cyclin D3 and protein kinase C, can in turn activate important processes linked to both hematopoietic stem cell proliferation and differentiation. 6, 7 In fact, not only is cyclin D3 highly expressed in the early stages of the hematopoietic differentiation, but it can also be associated with stem cell proliferation, as it has a role in the G1 phase of the cell cycle. 8, 9 On the other hand, PI-PLCbeta1 and protein kinase C signaling are also inter-connected with the PI3K/Akt/mTOR pathway, that is strictly linked to proliferation processes, particularly those associated with leukemogenesis.
Myelodysplastic syndromes (MDSs) are a heterogeneous group of hematological malignancies characterized by an increased although variable risk of evolution into acute myeloid leukemia (AML). MDS cells frequently show epigenetic abnormalities, such as aberrant hypermethylation of genes controlling cell proliferation or differentiation, which are usually associated with a poor prognosis in MDS. 10, 11 That is why most of the current therapeutic approaches for MDS patients are based on epigenetic therapy. Indeed, azacitidine is a cytosine nucleoside analog acting as a demethylating agent, which is currently used in high-risk MDS patients, being able to prolong the overall survival, delay the AML evolution and induce a favorable hematologic response, as compared with best supportive care therapy alone. 12, 13 In addition, azacitidine might potentially be a feasible and effective treatment also for lower-risk MDS subjects, including elderly and transfusion-dependent patients, who are refractory to or unsuited for treatment with growth factors and for whom limited treatment options are available. 14, 15 The molecular mechanisms underlying the effect of the epigenetic therapy are not completely understood, although it is well known that most of all cancer-related signaling pathways may be affected by hypermethylation 16, 17 and DNA methyltransferase inhibitors, such as azacitidine, which can induce the expression of methylated silenced gene products. 18 In the last few years, several studies demonstrated that nuclear inositide signaling pathways can be implicated in the MDS progression to AML. In fact, not only high-risk MDSs frequently show a specific activation of the Akt/mTOR axis, 19 but it has also been hypothesized that there exists an inverse correlation between the activation of Akt and PI-PLCbeta1. 20 Furthermore, it has been documented that the involvement of PI-PLCbeta1 in the MDS progression to AML is linked to both genetic and epigenetic processes. In fact, MDS patients can show a mono-allelic deletion of the PI-PLCbeta1 gene, which is associated with a higher risk of AML evolution. 21 As for the epigenetic processes, PI-PLCbeta1 can be a specific target for demethylating therapy, 20, 22, 23 as in high-risk MDS responder patients the epigenetic therapy can result in PI-PLCbeta1 promoter hypomethylation and PI-PLCbeta1 increased expression, which in turn is associated with an induction of cyclin D3.
Although the amount of PI-PLCbeta1 messenger RNA (mRNA) could be useful for assessing the clinical response to epigenetic treatments, 22, 23 little is known about the molecular and functional mechanisms linked with azacitidine effect on PI-PLCbeta1 promoter. That is why in the present study we further investigated the role of the epigenetic regulation of PI-PLCbeta1. We first examined whether azacitidine affects PI-PLCbeta1 promoter methylation, gene and protein expression also in low-risk MDS, then we assessed the effect of this drug on PI-PLCbeta1 downstream target cyclin D3. Furthermore, we studied the correlation between the demethylating effect of azacitidine and the degree of occupancy of PI-PLCbeta1 promoter, by Chromatin immunoprecipitation (ChIP) experiments, aiming at identifying the binding affinity of methyl-CpG-binding domain proteins (MBDs) and some transcription factors implicated in hematopoietic stem cell proliferation and differentiation. 31 patients who achieved complete remission, partial remission or hematologic improvements were considered as responders, whereas the remaining subjects were considered non-responders. Molecular analyses were performed only in patients who received a minimum of eight cycles of treatment.
MATERIALS AND METHODS
Isolation of mononuclear cells (MNCs) and CD34 þ cells from bone marrow or peripheral blood samples For in vitro experiments, MNCs and CD34 þ cells were isolated from MDS samples as previously described. 23 Samples were analyzed at baseline, and subsequently before each cycle of azacitidine administration. Further details can be found in the Supplementary Information.
Antibodies and reagents
For all in vitro experiments, antibodies and reagents were purchased from commercial sources, as described in the Supplementary Information.
Nucleic acids extraction
Genomic DNA and total RNA were isolated from cell lines, CD34 þ and total MNCs from MDS patients and healthy subjects by using the QIAamp DNA Blood Mini Kit and the RNeasy Mini Kit (both from Qiagen Ltd, Valencia, CA, USA) according to the manufacturer's protocol, and RNA was retro-transcribed as previously described. 22 Bisulfite DNA modification and real-time methylation-specific PCR DNA was bisulfite converted by the MOD50 kit (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer's protocol, and PI-PLCbeta1 promoter methylation was quantified as described elsewhere. 22 
Analysis of gene and protein expression
The expression of several genes belonging to the nuclear inositide pathway was quantified by using a specific TaqMan real-time PCR method (Applied Biosystems, Foster City, CA, USA), as described elsewhere. 22 The protein amount was assessed by immunocytochemical analyses, as previously illustrated. 23 Further details can be found in the Supplementary Information.
Computational analysis of PI-PLCbeta1 promoter sequence
The softwares MatInspector (Genomatix, Ann Arbor, MI, USA) and AliBaba 2.1 (Biobase GmbH, Wolfenbuettel, Germany), which employ the consensus sequences collected in the TRANSFAC library, 32, 33 were used for predicting the putative binding sites for transcription factors within the PI-PLCbeta1 promoter sequence.
ChIP analysis
ChIP assays were performed using the ChIP Imprint kit (Sigma-Aldrich), following the manufacturer's instructions. Chromatin was sonicated into fragments B500 bp in size and immunoprecipitation was performed with specific primary antibodies. Further details can be found in the Supplementary Information.
RESULTS

PI-PLCbeta1 promoter methylation in low-risk MDS patients at baseline and during azacitidine treatment
The status of PI-PLCbeta1 promoter methylation was analyzed before and during azacitidine administration ( Figure 1 and Supplementary Table 1) . PI-PLCbeta1 methylation in CD34 þ cells and MNCs did not show significant differences (data not shown), therefore all subsequent analyses were performed on MNCs only, because of the limited number of CD34 þ cells for each patient. As compared with the pretreatment amount, and considering the healthy subjects as the calibrator, responder patients demonstrated a marked decrease in PI-PLCbeta1 promoter methylation (Student's t-test, Po0.05 vs baseline, 95% CI À1.16 to À0.39), whereas patients refractory to azacitidine or treated with only supportive care displayed almost constant levels of promoter methylation (Student's t-test, P40.05 vs baseline, 95% CI À0.74 to þ 0.54 for non-responders; Student's t-test, P40.05, 95% CI À0.86 to þ 0.57 for patients who received only best supportive care). Notably, 15 patients showed a significant reduction of PI-PLCbeta1 methylation, with a statistically significant difference between pre-and post-treatment. In contrast, nine cases showed almost constant levels of PI-PLCbeta1 promoter methylation, while two cases displayed a slight increase, as compared with baseline (Supplementary Table 1 ).
PI-PLCbeta1 gene and protein expression in low-risk MDS patients at baseline and during azacitidine treatment As there was a stronger correlation between PI-PLCbeta1b splicing variant and the clinical response (data not shown), which is consistent with our previous data on high-risk MDS, 22 our gene expression analyses focused only on the nuclear splicing variant PIPLCbeta1b, named as PI-PLCbeta1 throughout all the text. As shown in Figure 1 and Supplementary Table 1 , azacitidine induced a statistically significant increase in PI-PLCbeta1 mRNA in responders (Student's t-test, Po0.05 vs baseline, 95% CI þ 0.49 to þ 1.12), reaching a maximum peak at the 4th and at the 8th cycle, whereas neither non-responders nor patients treated with best supportive care only did not show significant differences (Student's t-test, P40.05 vs baseline, 95% CI À0.13 to þ 0.76 for non-responders; Student's t-test, P40.05, 95% CI À0.39 to þ 0.42 for patients treated with best supportive care only). Interestingly, 15 patients showed a significant increase in PI-PLCbeta1 gene expression, with a statistically significant difference between pre-and posttreatment. In contrast, nine cases showed almost constant levels of PI-PLCbeta1 gene expression, while two cases displayed a slight decrease, as compared with baseline. Moreover, there was a statistically significant inverse correlation between PI-PLCbeta1 gene expression and promoter methylation during azacitidine administration within individual patients (Paired Student's t-test). The slight difference between the course of PI-PLCbeta1 methylation and gene expression may be due to the different methodology, as Sybr Green and Taqman have a different sensitivity. PIPLCbeta1 protein levels, assessed only by immunocytochemical investigations due to the limited number of MDS cells available for each sample, confirmed the mRNA analyses for responders and non-responders (Figure 1) , whereas no significant difference in PIPLCbeta1 protein expression was detected for patients treated with only best supportive care (data not shown).
Cyclin D3 gene and protein expression in low-risk MDS patients during azacitidine treatment Azacitidine induced an increase in cyclin D3 gene and protein expression (Figure 2 and Supplementary Table 1) . Indeed, the increase between cyclin D3 gene expression and baseline, calculated as a percentage rate on the pretreatment level of the same patient, was statistically significant for responders (Student's ttest, Po0.05 vs baseline, 95% CI À0.39 to þ 1.27), whereas both non-responders and patients treated with best supportive care only showed almost constant levels of cyclin D3 mRNA (Student's t-test P40.05 vs baseline, 95% CI À0.70 to þ 0.97 for non-responders; Student's t-test, P40.05, 95% CI À0.63 to þ 0.72 for patients treated with best supportive care only). Interestingly, cyclin D3 mRNA reached a maximum at the 5th cycle and increased again at the 8th cycle, with stable high levels between the 5th and the 8th cycle. As for protein analysis, only immunocytochemical experiments were performed, given the limited number of MDS cells available for each MDS sample. In particular, cyclin D3 protein amount showed an increase in responders and almost constant levels in non-responders (Figure 2) , whereas patients treated with only best supportive care did not show any significant difference in cyclin D3 protein expression (data not shown).
Selection of transcription factors within PI-PLCbeta1 promoter sequence
We previously demonstrated that the PI-PLCbeta1 Island #2 is hypermethylated in high-risk MDS patients and can be a specific target for azacitidine treatment. 22 Here, we assessed the presence of putative binding sites for transcription factors within this region. In particular, considering the transcription start site as þ 1, the combined computational analysis performed with two different softwares (MatInspector and AliBaba) showed the following binding sites, from left to right (Figure 3 ): c-myb (from À719 to À705); Sp1 (from À647 to À638); CEBPa (from À622 to À613); and MZF-1 (from À537 to À527). As all of these binding sites covered a region of about 280-bp upstream the beginning of the PI-PLCbeta1 gene coding sequence (À780 to À500), all subsequent analyses for evaluating the degree of occupancy of the PI-PLCbeta1 promoter within the Island#2 were carried out by applying a Sybr-Green real-time PCR method with primers designed to amplify this specific fragment.
Recruitment of transcription factors to PI-PLCbeta1 promoter in low-risk MDS patients at baseline and during azacitidine treatment To assess the degree of recruitment to the PI-PLCbeta1 promoter of the selected transcription factors (Sp1, CEBPa, c-myb and MZF-1) in vivo, we performed ChIP assays in low-risk MDS before and during azacitidine treatment. Neither patients treated with only best supportive care nor non-responder patients showed any significant difference in the binding of any of the selected Table 2 ). In contrast, responder patients displayed changes in the recruitment of the selected transcription factors to PI-PLCbeta1 promoter during epigenetic therapy (Figure 4 and Supplementary Table 2 ). In particular, Sp1, CEBPa and MZF-1 showed a statistically significant increase in the degree of recruitment to PI-PLCbeta1 promoter during azacitidine treatment, as compared with baseline. On the contrary, c-myb displayed a low degree of occupancy of PIPLCbeta1 promoter at baseline, which slightly decreased during azacitidine therapy.
Recruitment of MBDs to PI-PLCbeta1 promoter in low-risk MDS patients at baseline and during azacitidine treatment To determine the degree of recruitment of MBDs to the PI-PLCbeta1 promoter sequence in vivo, we performed ChIP assays in low-risk MDS cells at baseline and during azacitidine treatment. Neither patients treated with only best supportive care nor non-responders displayed any significant difference in the binding of MBDs to PI-PLCbeta1 promoter before and during epigenetic treatment (Supplementary Table 2 ). On the contrary, responder patients showed changes in MBDs recruitment during azacitidine therapy ( Figure 5 and Supplementary Table 2 ). In particular, MBD3 and MBD4 showed low levels of binding to the PI-PLCbeta1 promoter before and during azacitidine administration, whereas MECP2, MBD1 and MBD2 demonstrated a high binding to PI-PLCbeta1 promoter at baseline, which decreased during azacitidine therapy.
DISCUSSION
Epigenetic processes are more and more important in normal and pathological conditions, as aberrant DNA methylation patterns or other changes in chromatin structure can result in an altered expression of genes implicated in cell proliferation and differentiation, which could be essential for cancer progression.
Demethylating therapies are now being tested in hematological malignancies, to investigate the functional implications of the epigenetic modifications in cancer development and to analyze the role of critical molecules as therapeutic targets. However, the functional role of DNA hypermethylation is not completely understood, nor it is the molecular effect of demethylating therapy on the modulation of the structure of silenced promoter genes.
Signal transduction pathways are often altered in cancer cells, and lipid signaling in disease is an important field of investigation. Indeed, PI-PLCbeta1, along with its downstream target cyclin D3, is a key player for hematopoietic stem cell proliferation and differentiation, and is implicated in the MDS progression to AML, via genetic and epigenetic mechanisms. 21, 22 Indeed, our group recently showed that PI-PLCbeta1 promoter might be a specific target for azacitidine, alone or in combination with histone deacetylase inhibitors, like valproic acid, and demethylation is usually associated with a favorable response to treatment. 22, 23 These findings were mostly observed in high-risk MDS. However, azacitidine is also effective in MDS patients at lower risk of AML evolution. 14, 15 That is why in this study we focused on low-risk MDS subjects (IPSS low-or intermediate-1). We analyzed 30 low-risk MDS patients (26 under therapy with azacitidine and 4 treated with best supportive care only) at baseline and before the start of each cycle of azacitidine (that is, every 4 weeks, for a minimum of 8 cycles), in order to monitor the changes of PI-PLCbeta1 signaling during the therapy. As reported, the subjects showing a demethylation of PI-PLCbeta1 promoter and an increase in PI-PLCbeta1 expression had a favorable clinical response. Moreover, responder patients also displayed an induction of cyclin D3, thus confirming the activation of this Table reports all the details for each transcription factor, including the consensus sequences (capital letters indicate highly conserved residues, while small letters are used for less well-conserved positions).
PI-PLCbeta1 downstream target during azacitidine therapy. On the contrary, neither patients refractory to azacitidine nor subjects treated with best supportive care only had significant changes in cyclin D3 or PI-PLCbeta1 methylation and expression.
Interestingly, responder patients showed a maximum induction of PI-PLCbeta1 gene expression at the 4th and at the 8th cycle of azacitidine, with high levels between the 4th and the 8th cycle. Moreover, also cyclin D3 increased in responder patients, reaching a maximum peak at the 5th cycle and showing another significant increase at the 8th cycle, which could lead to hypothesize another increase of cyclin D3 expression after the 8th cycle. This behavior, along with the amount of PI-PLCbeta1, hints at a correlation between these two molecules, in that cyclin D3 expression seems to follow and could therefore be dependent on PI-PLCbeta1 activation in MDS responder patients.
Being azacitidine a demethylating agent, we also analyzed the functional effect of this drug on the structure of PI-PLCbeta1 promoter. As azacitidine targets one specific region of the PI-PLCbeta1 promoter (À2340/À1), named as CpG Island #2, 22 our analyses focused on this particular region during the epigenetic therapy. We selected four transcription factors spanning over 280 bp (À780/À500) of the PI-PLCbeta1 promoter sequence within the Island #2. Interestingly, two of them (Sp1 and CEBPa) are mainly involved in the regulation of gene expression but, more importantly, the other two (c-myb and MZF-1) are typically linked to the hematopoietic system. In fact, c-myb is required for regulating the proliferation and survival of normal myeloid progenitors and leukemic blast cells, while MZF-1 is usually associated with the differentiation of the hematopoietic stem cells. 34, 35 Stemming from these data, we carried out specific ChIP experiments on MDS samples at baseline and during azacitidine treatment. In our low-risk MDS patients, the four selected transcription factors were only partially recruited to PI-PLCbeta1 promoter before the start of epigenetic therapy. On the other hand, and specifically in MDS patients responding to azacitidine therapy, the recruitment of three of the four transcription factors (Sp1, CEBPa and MZF-1) increased during hypomethylating treatment. In contrast, even after azacitidine exposure, c-myb showed a low recruitment to PI-PLCbeta1 promoter. Interestingly, considering the role of MZF-1 in myeloid differentiation and the association of c-myb with hematopoietic stem cell proliferation, 34, 35 these results confirm the involvement of PI-PLCbeta1 in epigenetic mechanisms, and are particularly consistent with the hypothesis of a contribution of PI-PLCbeta1 in azacitidine-induced myeloid differentiation. Furthermore, we also studied the degree of recruitment of MBDs, which usually interact with methylated DNA and whose upregulation can be associated with cancer. 36 In particular, we studied the recruitment of MECP2, MBD1 and MBD2, that preferentially bind to methylated DNA, 37 as well as MBD3 and MBD4, which are not specifically associated with methylated DNA. 38 Our data show that in low-risk MDS responder patients, MBD3 and MBD4 demonstrated low binding levels before and during azacitidine administration. In contrast, MECP2, MBD1 and MBD2 were highly linked to PI-PLCbeta1 promoter during the pretreatment period, whereas their recruitment decreased after azacitidine exposure. These findings indicate that the MBDs which are preferentially associated with methylated DNA, constitutively occupy the PI-PLCbeta1 promoter and therefore likely contribute to the PI-PLCbeta1 basal inhibition. Moreover, these results also demonstrate that the MBD binding to PI-PLCbeta1 promoter is differentially regulated during demethylating therapy. As a consequence, it might be possible to speculate a different pattern of recruitment for MBDs and transcription factors during azacitidine therapy.
To our knowledge, this is the first time that a functional analysis of PI-PLCbeta1 promoter has been performed. Interestingly, our findings hint at an epigenetic regulation of PI-PLCbeta1, and therefore might be useful for opening new lines of investigation aiming to better understand the molecular pharmacology of azacitidine and possibly of other hypomethylating agents in MDS. In fact, our results could be important for disclosing the molecular mechanisms underlying the effect of epigenetic treatments in MDS patients, and might also pave the way for the development of innovative therapeutic strategies in MDS patients, based on nuclear inositide signaling pathways. Figure 5 . Recruitment of MBDs to PI-PLCbeta1 promoter in low-risk MDS patients responding to azacitidine therapy. At baseline, responder patients display low recruitment of all of the tested MBDs. After azacitidine therapy, the recruitment of MECP2, MBD1 and MBD2 to PI-PLCbeta1 promoter is significantly reduced, whereas MBD3 and MBD4 binding is not affected. Results are the mean of at least three independent experiments ± s.d. **Po0.01 vs pretreatment level. Agarose gel bands indicate specific PCR products obtained from the amplification of the PI-PLCbeta1 promoter with specific primers flanking the 280-bp-selected region. Normal IgG (IgG), RNA polymerase II (RNA Pol) and input chromatin DNA (Input) are used as a control for ChIP experiments with the specific primary antibodies (Ab).
